COVID-19: Neue Erkenntnisse über Blutplasma und Vitamin-D-Supplementierung bekannt heilpraxisnet.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heilpraxisnet.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with.
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
/PRNewswire/ A new drug reduced tumor size in patients who have lung cancer patients with a specific, disease-causing change in the gene KRAS, a study found..